Technical Analysis for CYTR - CytRx Corporation

Grade Last Price % Change Price Change
grade C 0.75 2.04% 0.02
CYTR closed up 2.04 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CYTR trend table...

Date Alert Name Type % Chg
Mar 22 Inside Day Range Contraction 0.00%
Mar 20 Stochastic Reached Overbought Strength 0.00%
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 19 MACD Bullish Signal Line Cross Bullish -1.33%
Mar 19 Expansion Breakout Bullish Swing Setup -1.33%
Mar 19 Pocket Pivot Bullish Swing Setup -1.33%
Mar 19 Volume Surge Other -1.33%
Mar 19 Earnings Movers Other -1.33%
Mar 19 Wide Bands Range Expansion -1.33%

Older signals for CYTR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. The company also has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas; completed its Phase 1b/2 clinical trial primarily in the same indication; and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. In addition, the company is evaluating a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Medicine Cancer Drugs Oncology Chemotherapy Monoclonal Antibodies Cancer Treatments Non Small Cell Lung Cancer Pharmacokinetics Tumors Advanced Solid Tumors Anthracyclines Metastatic Solid Tumors Evofosfamide
Is CYTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.05
52 Week Low 0.33
Average Volume 154,930
200-Day Moving Average 0.8614
50-Day Moving Average 0.6329
20-Day Moving Average 0.7029
10-Day Moving Average 0.7185
Average True Range 0.0455
ADX 30.08
+DI 20.2994
-DI 9.803
Chandelier Exit (Long, 3 ATRs ) 0.6435
Chandelier Exit (Short, 3 ATRs ) 0.7065
Upper Bollinger Band 0.792
Lower Bollinger Band 0.6138
Percent B (%b) 0.76
BandWidth 25.352113
MACD Line 0.0334
MACD Signal Line 0.0323
MACD Histogram 0.0011
Fundamentals Value
Market Cap 124.29 Million
Num Shares 166 Million
EPS -0.41
Price-to-Earnings (P/E) Ratio -1.84
Price-to-Sales 593.24
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.79
Resistance 3 (R3) 0.78 0.77 0.78
Resistance 2 (R2) 0.77 0.76 0.77 0.78
Resistance 1 (R1) 0.76 0.75 0.76 0.76 0.78
Pivot Point 0.74 0.74 0.74 0.74 0.74
Support 1 (S1) 0.73 0.73 0.74 0.74 0.72
Support 2 (S2) 0.72 0.73 0.72 0.72
Support 3 (S3) 0.71 0.72 0.72
Support 4 (S4) 0.71